Download as PDF
PreveCeutical - Provides Update on Scorpion Venom-Derived Peptide Program
Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, Frankfurt: 18H) is pleased to provide an update on the scorpion venom-derived peptide research and development program (the “Program”), which consists of identifying, extracting and sequencing peptides and proteins isolated from Caribbean Blue Scorpion venom.
The Program is progressing on schedule through the first of its three distinct phases. As previously announced, PreveCeutical has successfully separated several target scorpion venom-derived peptides and proteins (see news release dated August 11, 2017). The Company’s research team, led by Dr. Parekh, separated the proteins and peptides using both one-dimensional gel electrophoresis (“1DE”) and two-dimensional gel electrophoresis (“2DE”). 2DE is a robust, universally-accepted methodology for protein and peptide profiling, enabling their efficient separation from complex samples such as venom. Next, the Company’s research team is working to sequence the extracted peptides and proteins to determine their amino acid fingerprint.
In addition to 1DE and 2DE, PreveCeutical’s research team is currently using high-performance liquid chromatography (“HPLC”) to separate the target peptides and proteins. Using HPLC, the collected fractions of proteins and peptides are sequenced using a state-of-the-art Shimadzu PPSQ Protein Sequencer.
To facilitate comprehensive and definitive identification of the target peptides and proteins, PreveCeutical’s research team is also trialling the application of liquid chromatography tandem-mass spectrometry (LC-MS/MS) whereby the extracted peptides and proteins are fragmented using an ion source, and each fragment is identified by its mass-to-charge ratio. The generated data is then used in conjunction with cutting-edge software to retrospectively reconstruct the peptides and proteins and deduce their native sequence. Ultimately, this process is expected to enable PreveCeutical to generate Nature IdenticalTM peptides.
About PreveCeutical Medical Inc.
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; a Sol-gel platform for nose to brain delivery of medical compounds including cannabinoids; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom.
For more information about PreveCeutical, please visit
https://preveceutical.com/, follow us on Twitter:
https://twitter.com/PreveCeuticals and Facebook:
www.facebook.com/PreveCeutical.
On Behalf of the Board of Directors
“Stephen Van Deventer”
Chairman & CEO
For further information, please contact:
Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com
Forward-Looking Statements:
This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation, including the U.S. Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations and orientations regarding the future including the Company’s anticipated business plans, and the prospect of its ability and success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “pro forma”, “plans”, “expects”, “may”, “should”, “budget”, “schedules”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Such forward-looking statements include, among others, the ability of the Company to sequence the peptides and proteins and retrospectively reconstruct them, matters related to the Company’s current and planned research and development programs, and the Company’s ability and success in executing its proposed business plans. Actual results could differ from those projected in any forward-looking statements due to numerous factors including risks and uncertainties relating to the inability of the Company, to, among other things, pass pre-clinical screening processes, obtain any other required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, complete its research programs as planned, or obtain the financing required to carry out its planned future. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.